News

Drug discovery and development company Blueberry Therapeutics announced the appointment of Dr. Adrian Howd to its Board as an independent Non-Executive Director, strengthening its strategic, financial...

The market for new antibiotics is effectively failing. No novel class of drugs for the most virulent and persistent infections, those caused by Gram negative bacteria, has entered the clinic for over 50 years, and the drugs we have are steadily, i...

8th January 2020: Oxford & Manchester, UK. Cytox Ltd, which provides non-invasive, risk assessment and patient stratification tools for Alzheimer's disease and dementia, has appointed Dr Ian Gilham as the new Chairman of the Board. Dr Gil...

11th December, 2019, Alderley Park: UK Innovation & Science Seed Fund (UKI2S), Catapult Ventures’ GM&C Life Sciences Fund and Jonathan Milner are pleased to announced an investment in Pencil Biosciences, a novel gene modulation compa...

Moving from Push to Pull Nothing less than an entirely new model of drug development is needed if we are to create new antibiotics says Dr Peter Jackson. And it’s something NICE are finally taking seriously as they set about developing a ne...